The obesity pipeline: current strategies in the development of anti-obesity drugs (Q34578590)

3 August 2017

1 reference

title

The obesity pipeline: current strategies in the development of anti-obesity drugs (English)

1 reference

3 August 2017

0 references

Dunstan Cooke

1

1 reference

PubMed ID

17080028

3 August 2017

Steve Bloom

series ordinal

2

1 reference

3 August 2017

1 November 2006

1 reference

Nature Reviews Drug Discovery

3 August 2017

1 reference

3 August 2017

5

1 reference

3 August 2017

919-931

1 reference

3 August 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2136

3 August 2017

0 references

cites work

Obesity as a medical problem

1 reference

Safety of drug therapies used for weight loss and treatment of obesity

31 March 2020

1 reference

Orlistat for the treatment of obesity: rapid review and cost-effectiveness model

31 March 2020

1 reference

Sibutramine: its mode of action and efficacy

31 March 2020

1 reference

Clinical treatment of obesity: are drugs and surgery the answer?

31 March 2020

1 reference

Weighing in on bariatric surgery: procedure use, readmission rates, and mortality

31 March 2020

1 reference

G protein-coupled receptors in regulation of body weight

31 March 2020

1 reference

Valvular heart disease associated with fenfluramine-phentermine

31 March 2020

1 reference

A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine

31 March 2020

1 reference

WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity

31 March 2020

1 reference

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

31 March 2020

1 reference

Molecular characterization of a peripheral receptor for cannabinoids

31 March 2020

1 reference

The cannabinoid receptors.

31 March 2020

1 reference

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis

31 March 2020

1 reference

Leptin-regulated endocannabinoids are involved in maintaining food intake

31 March 2020

1 reference

Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice

31 March 2020

1 reference

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

31 March 2020

1 reference

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

31 March 2020

1 reference

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

31 March 2020

1 reference

Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist.

31 March 2020

1 reference

Topiramate: a review of preclinical, pharmacokinetic, and clinical data

31 March 2020

1 reference

Psychotropic drugs in the treatment of obesity: what promise?

31 March 2020

1 reference

Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women

31 March 2020

1 reference

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

31 March 2020

1 reference

The regulation of appetite

31 March 2020

1 reference

Short-term effects of growth hormone on fuel oxidation and regional substrate metabolism in normal man

31 March 2020

1 reference

Action of growth hormone in adipose tissue

31 March 2020

1 reference

Effects of tyrosine kinase inhibitors on tyrosine phosphorylations and the insulin-like effects in response to human growth hormone in isolated rat adipocytes

31 March 2020

1 reference

Adult growth hormone deficiency

31 March 2020

1 reference

Adverse events during growth hormone therapy

31 March 2020

1 reference

Positional cloning of the mouse obese gene and its human homologue

31 March 2020

1 reference

The regulation of food intake by peptides

31 March 2020

1 reference

Gastrointestinal satiety signals I. An overview of gastrointestinal signals that influence food intake

31 March 2020

1 reference

Gastrointestinal satiety signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide

31 March 2020

1 reference

Pharmacotherapy of obesity.

31 March 2020

1 reference

Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters.

31 March 2020

1 reference

Peptide YY levels are elevated after gastric bypass surgery.

31 March 2020

1 reference

31 March 2020

1 reference

Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides

31 March 2020

1 reference

Human distribution and release of a putative new gut hormone, peptide YY

31 March 2020

1 reference

A new molecular form of PYY: structural characterization of human PYY(3-36) and PYY(1-36)

31 March 2020

1 reference

Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36

31 March 2020

1 reference

Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide

31 March 2020

1 reference

Gut hormone PYY(3-36) physiologically inhibits food intake

31 March 2020

1 reference

PYY3-36 as an anti-obesity drug target.

31 March 2020

1 reference

Inhibition of food intake in obese subjects by peptide YY3-36

31 March 2020

1 reference

Effect of peptide YY3-36 on food intake in humans

31 March 2020

1 reference

Peptide YY and appetite control

31 March 2020

1 reference

The gut hormone peptide YY regulates appetite.

31 March 2020

1 reference

Attenuated peptide YY release in obese subjects is associated with reduced satiety.

31 March 2020

1 reference

Distribution and release of human pancreatic polypeptide

31 March 2020

1 reference

Characterization of the effects of pancreatic polypeptide in the regulation of energy balance

31 March 2020

1 reference

Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice.

31 March 2020

1 reference

Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome

31 March 2020

1 reference

Pancreatic polypeptide reduces appetite and food intake in humans

31 March 2020

1 reference

The role of leptin in human obesity and disease: a review of current evidence

31 March 2020

1 reference

Factors promoting and ameliorating the development of obesity

31 March 2020

1 reference

Obesity wars: molecular progress confronts an expanding epidemic

31 March 2020

1 reference

Leptin regulation of neuroendocrine systems

31 March 2020

1 reference

31 March 2020

1 reference

Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects

31 March 2020

1 reference

Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial.

31 March 2020

1 reference

Effects of recombinant leptin therapy in a child with congenital leptin deficiency.

31 March 2020

1 reference

Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control

31 March 2020

1 reference

Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone

31 March 2020

1 reference

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes

31 March 2020

1 reference

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes

31 March 2020

1 reference

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

31 March 2020

1 reference

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients

31 March 2020

1 reference

Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes

31 March 2020

1 reference

Biological actions and therapeutic potential of the glucagon-like peptides

31 March 2020

1 reference

A role for glucagon-like peptide-1 in the central regulation of feeding

31 March 2020

1 reference

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

31 March 2020

1 reference

International Union of Pharmacology. XXXV. The glucagon receptor family

31 March 2020

1 reference

Incretin mimetics as emerging treatments for type 2 diabetes

31 March 2020

1 reference

31 March 2020

1 reference

Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects.

31 March 2020

1 reference

Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study

31 March 2020

1 reference

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

31 March 2020

1 reference

Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract

31 March 2020

1 reference

Oxyntomodulin inhibits food intake in the rat

31 March 2020

1 reference

Peripheral oxyntomodulin reduces food intake and body weight gain in rats.

31 March 2020

1 reference

Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats

31 March 2020

1 reference

Oxyntomodulin suppresses appetite and reduces food intake in humans

31 March 2020

1 reference

Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial

31 March 2020

1 reference

Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial

31 March 2020

1 reference

Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.

31 March 2020

1 reference

Oxyntomodulin: a cAMP-dependent stimulus of rat parietal cell function via the receptor for glucagon-like peptide-1 (7-36)NH2.

31 March 2020

1 reference

Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line

31 March 2020

1 reference

Rimonabant adds appetizing choice to slim obesity market

31 March 2020

1 reference

Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans

31 March 2020

1 reference

Identification and functional analysis of novel human melanocortin-4 receptor variants

31 March 2020

1 reference

Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin

31 March 2020

1 reference

Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans

31 March 2020

1 reference

The melanocortin agonist melanotan II increases insulin sensitivity in OLETF rats

31 March 2020

1 reference

CNS melanocortin system involvement in the regulation of food intake.

31 March 2020

1 reference

Assessment of a small molecule melanocortin-4 receptor-specific agonist on energy homeostasis

31 March 2020

1 reference

Manipulating central nervous mechanisms of food intake and body weight regulation by intranasal administration of neuropeptides in man.

31 March 2020

1 reference

Cell and molecular cell biology of melanin-concentrating hormone

31 March 2020

1 reference

Melanin-concentrating hormone and its receptors: state of the art.

31 March 2020

1 reference

A role for melanin-concentrating hormone in the central regulation of feeding behaviour

31 March 2020

1 reference

Molecular characterization of the melanin-concentrating-hormone receptor

31 March 2020

1 reference

Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1

31 March 2020

1 reference

Molecular cloning and functional characterization of MCH2, a novel human MCH receptor

31 March 2020

1 reference

Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R

31 March 2020

1 reference

Chronic MCH-1 receptor modulation alters appetite, body weight and adiposity in rats

31 March 2020

1 reference

Antiobesity effect of a melanin-concentrating hormone 1 receptor antagonist in diet-induced obese mice.

31 March 2020

1 reference

Melanin-concentrating hormone-1 receptor antagonism decreases feeding by reducing meal size

31 March 2020

1 reference

Pharmacotherapy for obesity

31 March 2020

1 reference

Pharmacological approaches to weight reduction: therapeutic targets

31 March 2020

1 reference

Zonisamide for weight loss in obese adults: a randomized controlled trial

31 March 2020

1 reference

A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group

31 March 2020

1 reference

Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity

31 March 2020

1 reference

Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study

31 March 2020

1 reference

Ghrelin is a growth-hormone-releasing acylated peptide from stomach

31 March 2020

1 reference

Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway.

31 March 2020

1 reference

Subcutaneous administration of ghrelin stimulates energy intake in healthy lean human volunteers

31 March 2020

1 reference

Ghrelin induces adiposity in rodents

31 March 2020

1 reference

Absence of ghrelin protects against early-onset obesity

31 March 2020

1 reference

Vaccination against weight gain

31 March 2020

1 reference

Beta 3-adrenoceptor: an update

31 March 2020

1 reference

Association of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns.

31 March 2020

1 reference

Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity

31 March 2020

1 reference

Time of Onset of Non-Insulin-Dependent Diabetes Mellitus and Genetic Variation in the β3-Adrenergic–Receptor Gene

31 March 2020

1 reference

Pharmacological treatment of obesity: therapeutic strategies

31 March 2020

1 reference

The gut and energy balance: visceral allies in the obesity wars

31 March 2020

1 reference

Peptide YY abnormalities in gastrointestinal diseases

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD2136

1 reference

3 August 2017

1 reference

PubMed ID

17080028